Might Gut Microbiota Be a Target for a Personalized Therapeutic Approach in Patients Affected by Atherosclerosis Disease?

In recent years, the increasing number of studies on the relationship between the gut microbiota and atherosclerosis have led to significant interest in this subject. The gut microbiota, its metabolites (metabolome), such as TMAO, and gut dysbiosis play an important role in the development of atherosclerosis. Furthermore, inflammation, originating from the intestinal tract, adds yet another mechanism by which the human ecosystem is disrupted, resulting in the manifestation of metabolic diseases and, by extension, cardiovascular diseases. The scientific community must understand and elucidate these mechanisms in depth, to gain a better understanding of the relationship between atherosclerosis and the gut microbiome and to promote the development of new therapeutic targets in the coming years. This review aims to present the knowledge acquired so far, to trigger others to further investigate this intriguing topic.

Automated summary

In recent years, there has been a growing number of studies on the relationship between the gut microbiota and atherosclerosis, generating significant interest. The gut microbiota, its metabolites, and gut dysbiosis have been found to play a crucial role in the development of atherosclerosis. Inflammation originating from the intestinal tract further disrupts the human ecosystem, leading to metabolic diseases and cardiovascular diseases. Understanding these mechanisms is essential for developing new therapeutic targets in the future.